Top

Published in:

Open Access 01-02-2014 | Original Contributions

Prophylaxis of Venous Thromboembolism with Low Molecular Weight Heparin in Bariatric Surgery: a Prospective, Randomised Pilot Study Evaluating Two Doses of Parnaparin (BAFLUX Study)

Authors: Davide Imberti, Edoardo Baldini, Matteo Giorgi Pierfranceschi, Alberto Nicolini, Concetto Cartelli, Marco De Paoli, Marcello Boni, Esmeralda Filippucci, Stefano Cariani, Giorgio Bottani

Published in: Obesity Surgery | Issue 2/2014

Abstract

Background

The optimal dose of low molecular weight heparin (LMWH) to prevent venous thromboembolism (VTE) after bariatric surgery remains controversial. The aim of this multicentre, open-label, pilot study was to evaluate the efficacy and safety of two different doses of the LMWH parnaparin administered to patients undergoing bariatric surgery.

Methods

Patients were randomised to receive 4,250 IU/day (group A) or 6,400 IU/day (group B) of parnaparin s.c. for 7–11 days. Bilateral colour Doppler ultrasound of the lower limb was performed before surgery and at the end of the treatment period. The primary efficacy outcome was a composite of asymptomatic and symptomatic deep vein thrombosis, symptomatic pulmonary embolism and death from any cause during treatment. The primary safety endpoint was major and clinically relevant non-major bleeding.

Results

A total of 258 patients underwent randomization; 8 subjects were excluded following the safety analysis. One hundred thirty-one patients [106 females; mean age, 40.3 years (standard deviation (SD) ±9.6); mean body mass index (BMI), 44.6 kg/m² (SD ±5.4)] were assigned to group A and 119 patients [93 females; mean age, 41.5 years (SD ±9.9); mean BMI, 44.2 kg/m² (SD ±5.4)] were assigned to group B. The rate of the primary efficacy outcome was 1.5 % (two cases; 95 % confidence interval (CI), 0.2–6.0 %) in group A as compared with 0.8 % (one case; 95 % CI, 0.4–5.3 %) in group B (p = ns). The composite incidence of major bleeding and clinically relevant non-major bleeding was 6.1 % (eight cases; 95 % CI, 2.9–12.1 %) in group A and 5.0 % (six cases; 95 % CI, 2.1–11.1 %) in group B (p = ns).

Conclusions

A parnaparin dose of 4,250 IU/day seems suitable for VTE prevention in patients undergoing bariatric surgery.

Available only for authorised users

DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356(21):2176–83. Review. PubMed PMID: 17522401.PubMedCrossRef

Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–77S. Erratum in: Chest.2012 May;141(5):1369. PubMed PMID: 22315263; PubMed Central PMCID: PMC3278061.PubMed

Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMedCrossRef

Prystowsky JB, Morasch MD, Eskandari MK, et al. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. Surgery. 2005;138(4):759–63. discussion 763–5. PubMed PMID: 16269306.PubMedCrossRef

Rocha AT, de Vasconcellos AG, da Luz Neto ER, et al. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg. 2006;16(12):1645–55. Review. PubMed PMID: 17217642.PubMedCrossRef

Stroh C, Birk D, Flade-Kuthe R, et al. Evidence of thromboembolism prophylaxis in bariatric surgery—results of a quality assurance trial in bariatric surgery in Germany from 2005 to 2007 and review of the literature. Obes Surg. 2009;19(7):928–36.PubMedCrossRef

Gonzalez QH, Tishler DS, Plata-Munoz JJ, et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2004;18(7):1082–4. PubMed PMID: 15156394.PubMedCrossRef

Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19–24. PubMed PMID: 11868291.PubMedCrossRef

Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg. 2001;11(6):670–6. PubMed PMID: 11775562.PubMedCrossRef

10.

Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg. 2005;15(10):1368–74. PubMed PMID: 16354513.PubMedCrossRef

11.

Kothari SN, Lambert PJ, Mathiason MA. Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. Am J Surg. 2007;194(6):709–11. PubMed PMID: 18005758.PubMedCrossRef

12.

Raftopoulos I, Martindale C, Cronin A, et al. The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc. 2008;22(11):2384–91. PubMed PMID: 18622558.PubMedCrossRef

13.

Magee CJ, Barry J, Javed S, et al. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery. Surg Obes Relat Dis. 2010;6(3):322–5. PubMed PMID: 20510295.PubMedCrossRef

14.

Cotter SA, Cantrell W, Fisher B, et al. Efficacy of venous thromboembolism prophylaxis in morbidly obese patients undergoing gastric bypass surgery. Obes Surg. 2005;15(9):1316–20. PubMed PMID: 16259895.PubMedCrossRef

15.

Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):188S–203S. PubMed PMID: 15383472.PubMedCrossRef

16.

Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):381S–453S. PubMed PMID: 18574271.PubMedCrossRef

17.

Planès A, Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement—comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost. 1999;81(1):22–5. PubMed PMID: 10348714.PubMed

18.

Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis. 2008;4(5):625–31. PubMed PMID: 18261965.PubMedCrossRef

19.

Simoneau MD, Vachon A, Picard F. Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery. Obes Surg. 2010;20(4):487–91. PubMed PMID: 18931882.PubMedCrossRef

20.

Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis. 2010;29(2):233–40. PubMed PMID: 19902146.PubMedCrossRef

21.

Rowan BO, Kuhl DA, Lee MD, et al. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg. 2008;18(2):162–6. PubMed PMID: 18165884.PubMedCrossRef

22.

Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308–18. PubMed PMID: 12235452.PubMedCrossRef

23.

McKeage K, Keating GM. Parnaparin: a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs. 2008;68(1):105–22. PubMed PMID: 18081375.PubMedCrossRef

24.

Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S–530S. doi:10.1378/chest.11-2303. PubMed PMID: 22315270; PubMed Central PMCID: PMC3278058.PubMed

25.

Becattini C, Agnelli G, Manina G, et al. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. Surg Obes Relat Dis. 2012;8(1):108–15. PubMed PMID: 22014482.PubMedCrossRef

26.

Imberti D, Legnani C, Baldini E, et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thromb Res. 2009;124(6):667–71. PubMed PMID: 19482341.PubMedCrossRef

27.

Forestieri P, Quarto G, De Caterina M, et al. Prophylaxis of thromboembolism in bariatric surgery with parnaparin. Obes Surg. 2007;17(12):1558–62. PubMed PMID: 18004632.PubMedCrossRef

28.

Simone EP, Madan AK, Tichansky DS, et al. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc. 2008;22(11):2392–5. PubMed PMID: 18594915.PubMedCrossRef

29.

Wilson SJ, Wilbur K, Burton E, et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42–8. PubMed PMID: 11408748.PubMed

30.

Heizmann M, Baerlocher GM, Steinmann F, et al. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res. 2002;106(4–5):179–81. PubMed PMID: 12297122.PubMedCrossRef

31.

Brasileiro AL, Miranda Jr F, Ettinger JE, et al. Incidence of lower limbs deep vein thrombosis after open and laparoscopic gastric bypass: a prospective study. Obes Surg. 2008;18(1):52–7. PubMed PMID: 18080727.PubMedCrossRef

32.

Handeland GF, Abildgaard U, Holm HA, et al. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39(2):107–12. PubMed PMID: 2174783.PubMedCrossRef

33.

Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. 1998;128(8):663–77. Erratum in: Ann Intern Med 1998 Sep 1;129(5):425. PubMed PMID: 9537941.PubMedCrossRef

34.

Kearon C. Noninvasive diagnosis of deep vein thrombosis in postoperative patients. Semin Thromb Hemost. 2001;27(1):3–8. PubMed PMID: 11288945.PubMedCrossRef

Title: Prophylaxis of Venous Thromboembolism with Low Molecular Weight Heparin in Bariatric Surgery: a Prospective, Randomised Pilot Study Evaluating Two Doses of Parnaparin (BAFLUX Study)
Authors: Davide Imberti
Edoardo Baldini
Matteo Giorgi Pierfranceschi
Alberto Nicolini
Concetto Cartelli
Marco De Paoli
Marcello Boni
Esmeralda Filippucci
Stefano Cariani
Giorgio Bottani
Publication date: 01-02-2014
Publisher: Springer US
Published in: Obesity Surgery / Issue 2/2014
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-013-1105-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prophylaxis of Venous Thromboembolism with Low Molecular Weight Heparin in Bariatric Surgery: a Prospective, Randomised Pilot Study Evaluating Two Doses of Parnaparin (BAFLUX Study)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Long-Term Results of a Prospective Comparison of Roux-en-Y Gastric Bypass versus a Variant of Biliopancreatic Diversion in a Non-Superobese Population (BMI 35–50 kg/m2)

Controversy Surrounding ‘Mini’ Gastric Bypass

Excess Body Weight Loss is Associated with Nonpathological Gait Patterns in Women 4 to 5 Years After Bariatric Surgery

Systemic Lidocaine to Improve Quality of Recovery after Laparoscopic Bariatric Surgery: A Randomized Double-Blinded Placebo-Controlled Trial

Development of Ulcer Disease After Roux-en-Y Gastric Bypass, Incidence, Risk Factors, and Patient Presentation: A Systematic Review

The Relationship of Pre-Operative Health Status to Sustained Outcome in Gastric Bypass Surgery